swisspartners Ltd. acquired a new position in shares of CureVac (NASDAQ:CVAC) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,410 shares of the company’s stock, valued at approximately $219,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. AlphaMark Advisors LLC acquired a new stake in CureVac during the 1st quarter valued at approximately $30,000. Citigroup Inc. boosted its position in shares of CureVac by 565.0% during the 4th quarter. Citigroup Inc. now owns 665 shares of the company’s stock valued at $54,000 after purchasing an additional 565 shares in the last quarter. Advisors Asset Management Inc. acquired a new stake in CureVac during the first quarter worth approximately $83,000. Virtus ETF Advisers LLC bought a new stake in CureVac in the fourth quarter worth approximately $198,000. Finally, Compagnie Lombard Odier SCmA acquired a new position in CureVac in the first quarter valued at approximately $226,000. Institutional investors own 7.16% of the company’s stock.
A number of research analysts recently issued reports on the stock. Credit Suisse Group began coverage on shares of CureVac in a research report on Monday, April 26th. They set an “underperform” rating on the stock. Guggenheim began coverage on CureVac in a research note on Monday, May 3rd. They set a “buy” rating for the company. Finally, Zacks Investment Research lowered CureVac from a “buy” rating to a “hold” rating in a report on Friday, April 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $75.25.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza.
Featured Article: Sell-Side Analysts
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC).
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.